CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
16 results
Search Results
Now showing 1 - 10 of 16
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genome-wide tandem repeat expansions modify schizophrenia risk in the presence of a 22q11.2 deletion(Springer Science and Business Media LLC, 2026-04-15) ;Muyang Cheng ;Yue Yin ;Worrawat Engchuan ;Tracy HeungKathleen Angkustsiri1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence of Parkinson's Disease in 22q11.2 Deletion Syndrome: A Multicenter Study(Wiley, 2025-02-07) ;Emma N.M.M. von Scheibler ;Ann Swillen; ;Nikolai Gil D. ReyesAnthony E. LangBackground deletion syndrome (22q11.2DS) has been associated with increased risk of early‐onset Parkinson's disease (PD).</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To determine the prevalence and predictors of PD in a large international 22q11.2DS sample.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The sample comprised 856 adults (median age 28 (range 16–76) years; 53.0% female). PD was defined as clinical diagnosis by a neurologist (including bradykinesia, rest tremor and/or rigidity). Age‐specific risk and predictors of PD were analyzed using Kaplan–Meier curve and Cox regression.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>PD was present in 1.8% (95% CI: 0.9–2.6%) of the sample, 3.4% (95% CI: 2.2–4.6%) when including uncertain PD (clinical diagnosis or suspicion, but not meeting all criteria), and 14.0% (95% CI: 6.9–21.0%) of those aged ≥50 years. Median age at motor onset was 45 (range 20–66) years. None of the factors considered were associated with PD.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Given high PD prevalence and young onset, we propose periodic motor evaluations from age 40 years in 22q11.2DS1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome(2017) ;Anne S. Bassett ;Chelsea Lowther ;Daniele Merico ;Gregory CostainEva W. C. ChowScopus© Citations 77 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prenatal vs postnatal diagnosis of 22q11.2 deletion syndrome: cardiac and noncardiac outcomes through 1 year of age(2023) ;Lindsay R. Freud ;Stephanie Galloway ;T. Blaine Crowley ;Julie MoldenhauerAnn Swillen1Scopus© Citations 9 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Gathering the Stakeholder’s Perspective: Experiences and Opportunities in Rare Genetic Disease Research(2023) ;Lauren K. White ;T. Blaine Crowley ;Brenda Finucane ;Emily J. McClellanSarah Donoghue<jats:p>Background: Research participant feedback is rarely collected; therefore, investigators have limited understanding regarding stakeholders’ (affected individuals/caregivers) motivation to participate. Members of the Genes to Mental Health Network (G2MH) surveyed stakeholders affected by copy number variants (CNVs) regarding perceived incentives for study participation, opinions concerning research priorities, and the necessity for future funding. Respondents were also asked about feelings of preparedness, research burden, and satisfaction with research study participation. Methods: Modified validated surveys were used to assess stakeholders´ views across three domains: (1) Research Study Enrollment, Retainment, Withdrawal, and Future Participation; (2) Overall Research Experience, Burden, and Preparedness; (3) Research Priorities and Obstacles. Top box score analyses were performed. Results: A total of 704 stakeholders´ responded from 29 countries representing 55 CNVs. The top reasons for initial participation in the research included reasons related to education and altruism. The top reasons for leaving a research study included treatment risks and side effects. The importance of sharing research findings and laboratory results with stakeholders was underscored by participants. Most stakeholders reported positive research experiences. Conclusions: This study provides important insight into how individuals and families affected with a rare CNV feel toward research participation and their overall experience in rare disease research. There are clear targets for areas of improvement for study teams, although many stakeholders reported positive research experiences. Key findings from this international survey may help advance collaborative research and improve the experience of participants, investigators, and other stakeholders moving forward.</jats:p>3Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Chromatin regulators in the TBX1 network confer risk for conotruncal heart defects in 22q11.2DS(2023) ;Yingjie Zhao ;Yujue Wang ;Lijie Shi ;Donna M. McDonald-McGinnT. Blaine Crowley<jats:title>Abstract</jats:title><jats:p>Congenital heart disease (CHD) affecting the conotruncal region of the heart, occurs in 40–50% of patients with 22q11.2 deletion syndrome (22q11.2DS). This syndrome is a rare disorder with relative genetic homogeneity that can facilitate identification of genetic modifiers. Haploinsufficiency of <jats:italic>TBX1</jats:italic>, encoding a T-box transcription factor, is one of the main genes responsible for the etiology of the syndrome. We suggest that genetic modifiers of conotruncal defects in patients with 22q11.2DS may be in the <jats:italic>TBX1</jats:italic> gene network. To identify genetic modifiers, we analyzed rare, predicted damaging variants in whole genome sequence of 456 cases with conotruncal defects and 537 controls, with 22q11.2DS. We then performed gene set approaches and identified chromatin regulatory genes as modifiers. Chromatin genes with recurrent damaging variants include <jats:italic>EP400</jats:italic>, <jats:italic>KAT6A</jats:italic>, <jats:italic>KMT2C</jats:italic>, <jats:italic>KMT2D</jats:italic>, <jats:italic>NSD1, CHD7</jats:italic> and <jats:italic>PHF21A</jats:italic>. In total, we identified 37 chromatin regulatory genes, that may increase risk for conotruncal heart defects in 8.5% of 22q11.2DS cases. Many of these genes were identified as risk factors for sporadic CHD in the general population. These genes are co-expressed in cardiac progenitor cells with <jats:italic>TBX1</jats:italic>, suggesting that they may be in the same genetic network. The genes <jats:italic>KAT6A</jats:italic>, <jats:italic>KMT2C</jats:italic>, <jats:italic>CHD7</jats:italic> and <jats:italic>EZH2</jats:italic>, have been previously shown to genetically interact with <jats:italic>TBX1</jats:italic> in mouse models. Our findings indicate that disturbance of chromatin regulatory genes impact the <jats:italic>TBX1</jats:italic> gene network serving as genetic modifiers of 22q11.2DS and sporadic CHD, suggesting that there are some shared mechanisms involving the <jats:italic>TBX1</jats:italic> gene network in the etiology of CHD.</jats:p>Scopus© Citations 4 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome(2023) ;Erik Boot ;Sólveig Óskarsdóttir ;Joanne C.Y. Loo ;Terrence Blaine CrowleyAni Orchanian-CheffScopus© Citations 76 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome(2023) ;Sólveig Óskarsdóttir ;Erik Boot ;Terrence Blaine Crowley ;Joanne C.Y. LooJill M. ArganbrightScopus© Citations 50 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion(2020) ;Isabelle Cleynen ;Worrawat Engchuan ;Matthew S. Hestand ;Tracy HeungAaron M. HollemanScopus© Citations 98 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome(2020) ;Robert W. Davies ;Ania M. Fiksinski ;Elemi J. Breetvelt ;Nigel M. WilliamsStephen R. Hooper8Scopus© Citations 101